Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD1d–Natural Killer T (NKT) cell T-cell receptor (TCR) complex is a specialized immune signaling unit composed of the CD1d protein and the T-cell receptor of NKT cells. CD1d is a non-polymorphic, MHC class I-like molecule that functions to present lipid-based antigens, rather than peptides, to the immune system (UniProt P15813). The interaction between the CD1d-lipid complex and the semi-invariant TCR of NKT cells (Vα24-Jα18 in humans) triggers the rapid secretion of a broad range of cytokines, including IFN-gamma and IL-4, which can modulate both innate and adaptive immune branches (PubMed: 24549450). This complex is a major therapeutic target in oncology and infectious diseases, as NKT cell activation can stimulate potent anti-tumor or anti-pathogen responses. Drugs like alpha-galactosylceramide (α-GalCer) and its derivatives act as agonists by binding to the CD1d hydrophobic pocket to facilitate TCR recognition (PubMed: 11544199). However, therapeutic application is challenged by the potential for NKT cell anergy and the risk of systemic cytokine release syndrome (PubMed: 17449723).
Agonist glycolipids bind to the hydrophobic binding groove of the CD1d molecule; the resulting CD1d-lipid complex is then recognized by the semi-invariant T-cell receptor (TCR) of Natural Killer T (NKT) cells, leading to TCR ligation, intracellular signaling, and the rapid secretion of Th1 and Th2 cytokines (PubMed: 24549450).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD1d–Natural Killer T cell T-cell receptor complex (CD1d–NKT TCR) (CD1d–NKT TCR).